Literature DB >> 22230418

Rheumatoid arthritis: a complication of aromatase inhibitor therapy?

V Bruzzese, C Hassan, A Zullo, G Zampa.   

Abstract

We report the case of a 56-year-old woman treated with aromatase inhibitors for a breast cancer. Following one year of such therapy, the patient presented with widespread osteoarthrealgia. The clinical picture worsened 3 years later when the pain became more severe with swelling and stiffness involving several joints in a symmetric fashion. Biochemical analysis showed an increase of ESR, CRP and rheumatoid factor, as well as of anti-CCP antibodies. The x-ray was compatible with a diagnosis of rheumatoid arthritis (RA). Therapy with methotrexate, prednisol one, bisphosphonates and vitamin D was started, achieving a quick clinical remission. Aromatase inhibitors have been shown to alter the distribution of Th1/Th2 lymphocytes and increase the level of RANKL. A possible role of aromatase inhibitors in RA development has been further addressed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22230418     DOI: 10.1177/039463201102400430

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Breast cancer survivorship symptom management: current perspective and future development.

Authors:  G van Londen; Eb Beckjord; Ma Dew; P Cuijpers; S Tadic; A Brufsky
Journal:  Breast Cancer Manag       Date:  2013-01

Review 2.  Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.

Authors:  Sara Tenti; Nicola Giordano; Maurizio Cutolo; Fabio Giannini; Antonella Fioravanti
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

3.  Using gene expression signatures to identify novel treatment strategies in gulf war illness.

Authors:  Travis J A Craddock; Jeanna M Harvey; Lubov Nathanson; Zachary M Barnes; Nancy G Klimas; Mary Ann Fletcher; Gordon Broderick
Journal:  BMC Med Genomics       Date:  2015-07-09       Impact factor: 3.063

4.  RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.

Authors:  Jingxuan Wang; Kangping Lu; Ying Song; Shu Zhao; Wenjie Ma; Qijia Xuan; Dabei Tang; Hong Zhao; Lei Liu; Qingyuan Zhang
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

Review 5.  Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects.

Authors:  Sara Tenti; Pierpaolo Correale; Sara Cheleschi; Antonella Fioravanti; Luigi Pirtoli
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.